Mechanistic insights into complement pathway inhibition by CR1 domain duplication

Area of Science:

• Immunology
• Biochemistry

Background:

• Complement receptor 1 (CR1) is a glycoprotein that binds complement fragments C3b and C4b.
• A soluble CR1 fragment, CSL040, acts as a potent complement inhibitor.

Purpose of the Study:

• To engineer soluble CR1 variants with enhanced or pathway-specific complement inhibitory potential.
• To investigate the impact of Long Homologous Repeat (LHR) domain duplications on CR1 function.

Main Methods:

• Generation of soluble CR1 variants with duplicated LHR domains (e.g., LHR-ABCC, LHR-BBCC).
• In vitro potency assays to assess complement inhibitory activity.
• Solution binding assays for C3b and C4b.

Main Results:

• LHR-ABCC showed enhanced alternative pathway inhibition compared to CSL040.
• LHR-BBCC exhibited reduced classical/lectin pathway activity but comparable alternative pathway activity.
• Duplication of the LHR-A domain had minimal impact on classical/lectin pathway inhibition.

Conclusions:

• CR1 domain duplication is a viable strategy for developing potent complement inhibitors.
• Specific domain duplications can modulate CR1 activity across different complement pathways.
• These variants offer insights into CR1-ligand interactions and potential therapeutic applications.